During last night’s earnings call, Chromadex CEO Rob Fried discussed the results of recent clinical trials using NAD+ boosting vitamin supplement Nicotinamide Riboside “NR”  (FAQs) (Anecdotes). Here’s what he said:

From the Q4 Earnings Call:

“Since the last quarter, there were a few key clinical studies completed.

The first study was one that I referenced in the last earnings call — the NR safe study, which was published in November and examined the safety of high-dose NR supplementation at 3,000 milligrams per day and the impact of NAD in clinical severity in patients with Parkinson’s disease.

The study concluded that high-dose NR supplementation is indeed safe and well tolerated with no related adverse events.

Additionally, NR was found to improve clinical symptoms of PD patients as measured by the Movement Disorder Society Unified Parkinson’s Disease Rating Scale, suggesting that improving NAD levels may have a symptomatic anti-Parkinson’s effect.

The second completed study investigated the effects of NR supplementation with and without resveratrol on individuals with peripheral artery disease or PAD.

The study concluded that NR supplementation had beneficial effects on the walking performance of patients with PAD and suggested that the addition of resveratrol did not provide for further improvements in the effects of NR.

Another notable study that was recently completed examined the effects of NR supplementation and metabolic dysfunction in Werner syndrome, a rare genetic disorder that causes premature aging characterized by metabolic abnormalities.

This phase one study is the first clinical study involving NR supplementation in Werner syndrome patients, and we eagerly await publication of the results which are anticipated later this year.

While the preliminary findings from the PAD clinical study and the pending publication of the Werner syndrome clinical study will warrant further investigation in larger clinical trials, we’re very excited about the potential of Niagen to offer therapeutic benefits for individuals with different ailments and orphan diseases”

Related

FOLLOW us on Twitter @RaisingNAD